Merck | MRK - Selling And Administration Expenses

Stock Price
112.61
Daily Change
2.34 2.12%
Monthly
4.81%
Yearly
12.85%
Q1 Forecast
106.87

Merck reported $2.63B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Abbott USD 3.13B 125M Dec/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
J&J USD 6.75B 831M Dec/2025
Medtronic 2.97B 159M Sep/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Prestige Brands USD 28.04M 419K Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
United Therapeutics USD 152M 60.5M Sep/2025
Zoetis USD 579M 29M Sep/2025